CTY CITY THERAPEUTICS INC
FollowCommon Stock, par value $0.0001 per share (common), issuer CIK 2143850
No 13F filer reports this security in the loaded quarters.
13D and 13G filers
Each filer's latest stake. The shares are the aggregate the reporting persons state, which can include entities that file no 13F.
- FMR LLC(group FMR LLC)
7,025,543 shares, 14% in a 13G as of 2026-10-30,0000315066-26-002961
Accepted , ingested - VIKING GLOBAL INVESTORS LP(group VIKING GLOBAL INVESTORS LP)
3,727,005 shares, 7% in a 13G as of 2026-10-19,0000905148-26-004557
Accepted , ingested - ARCH Venture Fund XII, L.P.(group ARCH Venture Partners XII, LLC)
13,692,507 shares, 25.6% in a 13D as of 2026-10-19,0001193125-26-432028
Accepted , ingested - Invus Global Management, LLC (group Invus Public Equities Advisors, LLC)
4,342,866 shares, 8.1% in a 13G as of 2026-10-16,0002005369-26-000056
Accepted , ingested
Insider trades
No Form 4 transaction on this security in the data.
Events
FMR LLC and 1 other reporting person reported 7,025,543 CTY shares, 14% of the class, as of 2026-10-30, in a 13G filed 2026-11-06. 0000315066-26-002961
Accepted , ingestedARCH Venture Fund XII, L.P. and 6 other reporting persons reported 13,692,507 CTY shares, 25.6% of the class, as of 2026-10-19, in a 13D filed 2026-10-26. 0001193125-26-432028
Accepted , ingestedVIKING GLOBAL INVESTORS LP and 9 other reporting persons reported 3,727,005 CTY shares, 7% of the class, as of 2026-10-19, in a 13G filed 2026-10-26. 0000905148-26-004557
Accepted , ingestedInvus Global Management, LLC and 7 other reporting persons reported 4,342,866 CTY shares, 8.1% of the class, as of 2026-10-16, in a 13G filed 2026-10-22. 0002005369-26-000056
Accepted , ingested